- Home
- VTYX vs ALEC Comparison
VTYX vs ALEC Comparison
Compare VTYX & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTYX
- ALEC
- Stock Information
- Founded
- VTYX 2018
- ALEC 2013
- Country
- VTYX United States
- ALEC United States
- Employees
- VTYX N/A
- ALEC N/A
- Industry
- VTYX Medicinal Chemicals and Botanical Products
- ALEC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VTYX Health Care
- ALEC Health Care
- Exchange
- VTYX Nasdaq
- ALEC Nasdaq
- Market Cap
- VTYX 154.9M
- ALEC 124.0M
- IPO Year
- VTYX 2021
- ALEC 2019
- Fundamental
- Price
- VTYX $8.09
- ALEC $1.32
- Analyst Decision
- VTYX Buy
- ALEC Hold
- Analyst Count
- VTYX 3
- ALEC 9
- Target Price
- VTYX $12.50
- ALEC $3.40
- AVG Volume (30 Days)
- VTYX 9.8M
- ALEC 5.2M
- Earning Date
- VTYX 11-06-2025
- ALEC 11-06-2025
- Dividend Yield
- VTYX N/A
- ALEC N/A
- EPS Growth
- VTYX N/A
- ALEC N/A
- EPS
- VTYX N/A
- ALEC N/A
- Revenue
- VTYX N/A
- ALEC $81,130,000.00
- Revenue This Year
- VTYX N/A
- ALEC N/A
- Revenue Next Year
- VTYX N/A
- ALEC $290.64
- P/E Ratio
- VTYX N/A
- ALEC N/A
- Revenue Growth
- VTYX N/A
- ALEC 46.77
- 52 Week Low
- VTYX $0.78
- ALEC $0.87
- 52 Week High
- VTYX $9.50
- ALEC $6.14
- Technical
- Relative Strength Index (RSI)
- VTYX 76.14
- ALEC 25.34
- Support Level
- VTYX $5.75
- ALEC $1.45
- Resistance Level
- VTYX $9.50
- ALEC $1.68
- Average True Range (ATR)
- VTYX 0.78
- ALEC 0.19
- MACD
- VTYX 0.33
- ALEC -0.11
- Stochastic Oscillator
- VTYX 76.85
- ALEC 1.42
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
About ALEC Alector Inc.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.